Head to Head Comparison: Mylan N.V. (MYL) versus NephroGenex (NRX)

Mylan N.V. (NASDAQ: MYL) and NephroGenex (NASDAQ:NRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitabiliy and risk.

Earnings & Valuation

This table compares Mylan N.V. and NephroGenex’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Mylan N.V. $11.61 billion 1.49 $3.80 billion $1.22 26.47
NephroGenex N/A N/A N/A N/A N/A

Mylan N.V. has higher revenue and earnings than NephroGenex.

Profitability

This table compares Mylan N.V. and NephroGenex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mylan N.V. 5.51% 22.42% 7.54%
NephroGenex N/A -211.97% -105.90%

Institutional and Insider Ownership

70.2% of Mylan N.V. shares are owned by institutional investors. 0.7% of Mylan N.V. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Mylan N.V. and NephroGenex, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mylan N.V. 0 8 11 2 2.71
NephroGenex 0 0 1 0 3.00

Mylan N.V. currently has a consensus price target of $48.16, indicating a potential upside of 49.14%. NephroGenex has a consensus price target of $17.50, indicating a potential upside of 12,391.08%. Given NephroGenex’s stronger consensus rating and higher probable upside, analysts plainly believe NephroGenex is more favorable than Mylan N.V..

Summary

Mylan N.V. beats NephroGenex on 8 of the 10 factors compared between the two stocks.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

About NephroGenex

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit